Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue European Respiratory Journal Année : 2018

Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review

Résumé

The relative efficacy of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that directly depletes eosinophils versus other IL-5-targeted treatments for patients with severe, uncontrolled asthma, is not yet fully characterised.We performed a matching-adjusted indirect comparison (MAIC) of benralizumab versus mepolizumab and reslizumab. Trials were selected through systematic review and evaluation of trial methods. Benralizumab patient-level data were weighted to match treatment effect-modifying patient characteristics of comparator trials before indirect efficacy comparisons.After matching adjustment, benralizumab and mepolizumab reduced exacerbations versus placebo by 52% and 49%, respectively (rate ratio [RR]: 0.94; 95% confidence interval [CI]: 0.78-1.13; N=1524) and reduced the rate of exacerbations requiring hospitalisation/emergency department visit by 52% and 52%, respectively (RR: 1.00; 95% CI: 0.57-1.75; N=1524). Benralizumab and mepolizumab similarly improved prebronchodilator forced expiratory volume in 1 second at 32 weeks (difference=0.03 L; 95% CI: -0.06-0.12; N=1443). Benralizumab and reslizumab patient populations were too dissimilar to generate a sufficient effective sample size to produce a reliable estimate for MAIC.MAIC is a robust way to indirectly compare efficacies of treatments from trials with heterogeneous patient populations. When baseline patient characteristics were matched across asthma trials, benralizumab and mepolizumab yielded similar efficacy.
Fichier principal
Vignette du fichier
Bourdin et al-ERJ-2018.pdf (323.47 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01894964 , version 1 (24-03-2020)

Identifiants

Citer

Arnaud Bourdin, Don Husereau, Nicolas Molinari, Sarowar Golam, Mohd Kashif Siddiqui, et al.. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. European Respiratory Journal, 2018, 52 (5), ⟨10.1183/13993003.01393-2018⟩. ⟨hal-01894964⟩
288 Consultations
88 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More